The fair value estimate for Thermo Fisher Scientific has shifted from US$686.64 to US$750.92, giving investors an updated anchor for thinking about the stock. This change sits within a wider mix of bullish and cautious analyst views that lean on Q3 2026 results, guidance and the debate around long term growth targets. As you read on, you will see how this evolving narrative fits together and how to keep track of future updates.
Stay updated as the Fair Value for Thermo Fisher Scientific shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Thermo Fisher Scientific.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms, including Argus, TD Cowen, Barclays, Stifel, BofA, Deutsche Bank, UBS, Morgan Stanley, Baird and CLSA, have raised price targets on Thermo Fisher Scientific, often following Q3 results or investor meetings that they describe as supportive of their updated views.
-
TD Cowen, Deutsche Bank and UBS point to factors such as Q3 performance, Patheon and AI exposure, pharma and biotech demand, and end market trends as supportive of Thermo Fisher Scientific's growth ambitions over the medium term.
-
RBC and Deutsche Bank refer to company execution and what they see as progress toward long term organic growth goals, while UBS highlights the potential for margin expansion and earnings growth as part of its constructive stance.
-
Argus cites a clean balance sheet and a 9% dividend hike as signals of management confidence, which some investors may view as relevant to Thermo Fisher Scientific's capital allocation story.
🐻 Bearish Takeaways
-
DZ Bank downgraded Thermo Fisher Scientific to Hold with a US$650 price target, which is below several of the more optimistic targets and signals a more neutral risk reward view.
-
RBC keeps a Sector Perform rating and flags structural risk around Thermo Fisher Scientific's 7% long term organic growth aspiration, which underscores that not all analysts see the growth targets as assured.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Thermo Fisher Scientific. See which could impact your investment.
How This Changes the Fair Value For Thermo Fisher Scientific
-
Fair value has moved from US$686.64 to US$750.92.
-
Revenue growth has been adjusted from 5.75% to 5.82%.
-
Net profit margin has been revised from 18.15% to 19.04%.
-
The future P/E has been updated from 31.0x to 31.6x.
-
The discount rate has shifted from 8.38% to 8.37%.
Never Miss an Update: Follow The Narrative
Narratives connect Thermo Fisher Scientific's business story to analyst forecasts and a fair value anchor. They update over time as new earnings, industry data and risks emerge.
Head over to the Simply Wall St Community and follow the Narrative on Thermo Fisher Scientific to stay up to date on:
-
How pharma and biotech demand, clinical trial activity and AI in drug development feed into Thermo Fisher Scientific's tools and services.
-
The impact of portfolio moves such as the Clario and Solventum deals, bioproduction capacity, and reshoring related projects on revenue mix and margins.
-
Key risks including slower academic and government funding, the earnings effect of the microbiology divestiture, and the possibility that valuation multiples compress even if earnings follow analyst estimates.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TMO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
